MORRISVILLE, N.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Science 37, the leader in expanding patient access to clinical trials, and Catalent ®, a global leader in enabling pharma, biotech, and consumer ...

Nov 5 (Reuters) - Contract drug manufacturer Catalent (CTLT.N), opens new tab, which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall ...

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, today announced that, at its ...

Over the past five years the share price of Catalent (CTLT) - a company focused on the provision of "differentiated development and manufacturing solutions for drugs, protein-based biologics, cell and ...

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced it has completed expansion ...

(Reuters) - Contract drug manufacturer Catalent, which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.

After Catalent CTLT twice delayed its fiscal-year third-quarter results, management stated during a business update call that it still needs more time to complete its earnings report. However, ...

After a lengthy delay, Catalent CTLT released its third-quarter 2023 financial results highlighted by a net loss of $227 million for the quarter, compared with net earnings of $141 million in the ...

Catalent Stockholders to Receive $63.50 Per Share in Cash, Representing a 47.5% Premium to the 60-day Volume-Weighted Average Price as of February 2, 2024 Novo Holdings has a proven track record of ...

Catalent is a partner for pharmaceutical and biotechnology companies, helping its customers to bring products to the market in a faster fashion. The company does this by providing oral, injectable and ...